Based on the Ibio Inc stock forecast from 1 analysts, the average analyst target price for Ibio Inc is USD 6.00 over the next 12 months. Ibio Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Ibio Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Ibio Inc’s stock price was USD 3.18. Ibio Inc’s stock price has changed by +8.16% over the past week, +29.80% over the past month and +189.12% over the last year.
No recent analyst target price found for Ibio Inc
No recent average analyst rating found for Ibio Inc
Company Overview Ibio Inc
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; ShieldTx, an antibody masking technology that enables the creation of conditionally activated antibodies; StableHu, an AI antibody-optimizing technology; and AI epitope steering technology that guides antibodies against the desired regions of the target protein. Its product pipelines for cardiometabolic disease area include IBIO-101, an anti-CD25 Mab that binds and depletes immunosuppressive regulatory treg cells to inhibit the growth of solid tumors; CCR8, an antibody that enhance the body's immune response against cancer cells; and trophoblast cell surface antigen 2, a monoclonal antibodies, as well as MUC16 and Target 5 antibodies. In addition, the company is developing EGFRvIII, an antibody therapeutics that targets EGFRvIII protein with the aim to address these cancer types without affecting healthy cells. It has a collaboration agreement with AstralBio to discover and develop novel antibodies for obesity and other cardiometabolic diseases. iBio, Inc. was incorporated in 2008 and is headquartered in San Diego, California. Read Less
iBio, Inc., a preclinical stage biotechnology company, engages in the development of artificial intelligence (AI) antibodies solutions for cancer, and other diseases. The company's technology platforms include EngageTx that provides improved CD3 T-cell engager antibody panel; Shi...Read More
Frequently Asked Questions About Ibio Inc (IBIO) Stock
Based on ratings from 1 analysts Ibio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on IBIO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IBIO is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on IBIO's stock to indicate if its overvalued.
The last closing price of IBIO's stock was USD 3.18.
The most recent market capitalization for IBIO is USD 0.02B.
Based on targets from 1 analysts, the average taret price for IBIO is projected at USD 6.00 over the next 12 months.
This means that IBIO's stock price may go up by +88.68% over the next 12 months.
We can't find any ETFs which contains Ibio Inc's stock.
As per our most recent records Ibio Inc has 16 Employees.
Ibio Inc's registered address is 11750 Sorrento Valley Road, San Diego, CA, United States, 92121.
You can get more information about it from Ibio Inc's website at https://ibioinc.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Ibio Inc (IBIO) Stock
Based on ratings from 1 analysts Ibio Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 1 buy, sell and hold ratings.
Unfortunately we do not have enough data on IBIO's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for IBIO is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
Unfortunately we do not have enough data on IBIO's stock to indicate if its overvalued.
The last closing price of IBIO's stock was USD 3.18.
The most recent market capitalization for IBIO is USD 0.02B.
Based on targets from 1 analysts, the average taret price for IBIO is projected at USD 6.00 over the next 12 months.
This means that IBIO's stock price may go up by +88.68% over the next 12 months.
We can't find any ETFs which contains Ibio Inc's stock.
As per our most recent records Ibio Inc has 16 Employees.
Ibio Inc's registered address is 11750 Sorrento Valley Road, San Diego, CA, United States, 92121.
You can get more information about it from Ibio Inc's website at https://ibioinc.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for IBIO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
